Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 55
Filtrar
Más filtros











Intervalo de año de publicación
1.
Medicina (B Aires) ; 84(5): 922-928, 2024.
Artículo en Español | MEDLINE | ID: mdl-39399932

RESUMEN

INTRODUCTION: Water and electrolyte disturbances associated with colistin are understudied adverse effects in the medical literature. We aim to evaluate their incidence in hospitalized older adult patients. MATERIALS AND METHODS: A longitudinal retrospective study of the interrupted time series type was conducted on patients admitted to Dr. César Milstein Hospital. We included adults aged 65 and older who received colistin with normal serum potassium, magnesium, and calcium at the outset. Electrolyte values were collected before, during and after suspending the antibiotic. Values were compared using non-parametric tests, and a multivariate linear regression model with robust intervals was performed to assess sociodemographic and clinical characteristics associated with serum concentrations. RESULTS: A total of 89 patients were included. The rate of hypokalemia was 77.5% (n=69), and factors associated with potassium decline included older age, increased creatinine levels, and longer colistin treatment duration. Serum magnesium disturbances were reported in 66 (79.5%) of the 83 patients evaluated. The decrease in both electrolytes was statistically significant in the measured times and both values normalized after 72 hours of stopping antibiotic therapy. The incidence of acute kidney injury during colistin treatment in patients with normal baseline creatinine was 63.6% (n = 42/66), and in those with abnormal baseline creatinine, it was 47.8% (n = 11/23). CONCLUSION: We report high rates of electrolyte disturbances in patients treated with colistin, with hypokalemia being the most frequent, showing resolution following discontinuation of antibiotic therapy. Continuous monitoring of electrolyte levels and renal function during colistin treatment is crucial.


Introducción: Los trastornos hidroelectrolíticos asociados a la colistina son efectos adversos poco estudiados en la literatura médica. Nos propusimos evaluar su incidencia en pacientes adultos mayores hospitalizados. Materiales y métodos: Se realizó un estudio longitudinal retrospectivo, del tipo serie de tiempo interrumpida, en pacientes internados mayores de 65 años que recibieron colistina, con potasio, magnesio y calcio séricos normales al inicio. Se recabaron valores de dichos electrolitos previo, durante y luego de suspender el antibiótico. Se compararon los valores mediante test no paramétricos y se realizó un modelo multivariado de regresión lineal con intervalos robustos para evaluar las características sociodemográficas y clínicas asociadas a las concentraciones séricas. Resultados: Se incluyeron 89 pacientes. La tasa de hipocalemia fue del 77.5% (n = 69) y las variables asociadas al descenso del potasio fueron mayor edad, aumento de creatininemia, y duración de tratamiento con colistina. Se informaron trastornos del magnesio en 66 (79.5%) de los 83 pacientes evaluados. El descenso de ambos electrolitos fue estadísticamente significativo en los tiempos medidos, y ambos normalizaron valores tras 72 horas de suspendida la antibioticoterapia. La incidencia de insuficiencia renal aguda en pacientes con creatinina basal normal fue del 63.6%, (42/66) y con creatinina basal anormal de 47.8% (11/23). Conclusión: En pacientes tratados con colistina, el trastorno más frecuente fue la hipocalemia, mostrando resolución tras la suspensión del antibiótico. Es importante la monitorización constante de los niveles de electrolitos y la función renal durante el tratamiento con colistina.


Asunto(s)
Antibacterianos , Calcio , Colistina , Hipopotasemia , Magnesio , Potasio , Humanos , Colistina/efectos adversos , Colistina/sangre , Masculino , Femenino , Anciano , Estudios Retrospectivos , Magnesio/sangre , Antibacterianos/efectos adversos , Hipopotasemia/sangre , Hipopotasemia/inducido químicamente , Hipopotasemia/epidemiología , Anciano de 80 o más Años , Potasio/sangre , Calcio/sangre , Estudios Longitudinales , Factores de Tiempo , Desequilibrio Hidroelectrolítico/inducido químicamente , Desequilibrio Hidroelectrolítico/sangre , Desequilibrio Hidroelectrolítico/epidemiología , Lesión Renal Aguda/sangre , Lesión Renal Aguda/inducido químicamente , Lesión Renal Aguda/epidemiología
2.
J Antimicrob Chemother ; 79(10): 2598-2606, 2024 Oct 01.
Artículo en Inglés | MEDLINE | ID: mdl-39074040

RESUMEN

BACKGROUND: Progressive disseminated histoplasmosis is a significant issue in Latin America, particularly in Brazil, contributing to high mortality rates. OBJECTIVES: Our objectives were to comprehensively describe histoplasmosis treatment with various amphotericin B (AmB) formulations, including mortality rates, adverse effects and risk factors for mortality. METHODS: This multicentre retrospective cohort study (January 2014-December 2019) evaluated medical records of patients with proven or probable histoplasmosis treated with at least two doses of AmB in seven tertiary medical centres in Brazil. We assessed risk factors associated with death during hospitalization using univariate and multivariate analyses. RESULTS: The study included 215 patients, mostly male (n = 158, 73%) with HIV infection (n = 187, 87%), and a median age of 40 years. Only 11 (5%) patients initiated treatment with liposomal amphotericin B (L-AmB). Amphotericin B deoxycholate (D-AmB) was administered to 159 (74%) patients without changes in the treatment. The overall mortality during hospitalization was 23% (50/215). Variables independently associated with mortality were use of D-AmB (OR 4.93) and hospitalization in ICU (OR 9.46). There was a high incidence of anaemia (n = 19, 90%), acute kidney injury (n = 96, 59%), hypokalaemia (n = 73, 55%) and infusion reactions (n = 44, 20%) during treatment. CONCLUSIONS: We found that D-AmB was the main formulation, which was also associated with a higher mortality rate. Lipid formulations of AmB have become more readily available in the public health system in Brazil. Further studies to evaluate the effectiveness of L-AmB will likely show improvements in the treatment outcomes for patients with disseminated histoplasmosis.


Asunto(s)
Anfotericina B , Antifúngicos , Histoplasmosis , Humanos , Anfotericina B/uso terapéutico , Anfotericina B/efectos adversos , Masculino , Histoplasmosis/tratamiento farmacológico , Histoplasmosis/mortalidad , Femenino , Estudios Retrospectivos , Adulto , Antifúngicos/uso terapéutico , Antifúngicos/efectos adversos , Persona de Mediana Edad , Brasil/epidemiología , Ácido Desoxicólico/uso terapéutico , Ácido Desoxicólico/efectos adversos , Factores de Riesgo , Combinación de Medicamentos , Adulto Joven , Hospitalización/estadística & datos numéricos , Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/complicaciones , Infecciones por VIH/mortalidad , Anciano , Hipopotasemia/inducido químicamente , Hipopotasemia/mortalidad
3.
Curr Drug Saf ; 18(1): 107-111, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-35469572

RESUMEN

BACKGROUND: Prostate cancer (PC) is the most common type of neoplasm in men and the fourth leading cause of mortality in Brazil. The prostate cancer refractory metastatic castration can be treated with abiraterone acetate (AA). CASE PRESENTATION: Its use has been associated with increased survival. However, there are also side effects associated with the use of this drug, such as severe electrolyte disturbances. CONCLUSION: The objective is to report the clinical case of a patient with castration-resistant metastatic prostate cancer who developed ascending flaccid paralysis secondary to severe hypokalemia, probably due to hyperaldosteronism secondary to the use of Abiraterone Acetate, despite the use of Prednisone.


Asunto(s)
Hipopotasemia , Neoplasias de la Próstata Resistentes a la Castración , Masculino , Humanos , Acetato de Abiraterona/efectos adversos , Neoplasias de la Próstata Resistentes a la Castración/tratamiento farmacológico , Neoplasias de la Próstata Resistentes a la Castración/patología , Hipopotasemia/inducido químicamente , Hipopotasemia/diagnóstico , Hipopotasemia/tratamiento farmacológico , Prednisona , Parálisis/inducido químicamente , Parálisis/diagnóstico , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos
4.
J Bras Nefrol ; 44(1): 112-115, 2022.
Artículo en Inglés, Portugués | MEDLINE | ID: mdl-33891671

RESUMEN

Polymyxins are antibiotics developed in the 1950s. Polymyxin-induced neurotoxicity has been often described in medical literature. The same cannot be said of nephrotoxicity or tubulopathy in particular. This report describes the case of a patient prescribed polymyxin B to treat a surgical wound infection, which led to significant increases in fractional excretion of calcium, magnesium, and potassium and subsequent persistent decreases in the levels of these ions, with serious consequences for the patient. Severe hypocalcemia, hypomagnesemia, and hypokalemia may occur during treatment with polymyxin. Calcium, magnesium and potassium serum levels must be monitored during treatment to prevent life-threatening conditions.


Asunto(s)
Lesión Renal Aguda , Hipocalcemia , Hipopotasemia , Lesión Renal Aguda/inducido químicamente , Humanos , Hipocalcemia/inducido químicamente , Hipocalcemia/tratamiento farmacológico , Hipopotasemia/inducido químicamente , Magnesio/efectos adversos , Polimixinas/efectos adversos
5.
Arch. pediatr. Urug ; 92(2): e305, dic. 2021. tab
Artículo en Español | LILACS, BNUY, UY-BNMED | ID: biblio-1278305

RESUMEN

Las afecciones respiratorias agudas son la primera causa de consulta e ingreso hospitalario en los meses de invierno, y entre ellas el asma ocupa un lugar preponderante. El salbutamol es un broncodilatador con eficacia demostrada en las exacerbaciones y se utiliza de primera línea en el tratamiento. El objetivo de la presente comunicación es analizar dos casos clínicos de niños asmáticos que presentaron efectos adversos al salbutamol y requirieron el ingreso en la Unidad de Terapia Intensiva. Se propone revisar los efectos adversos del salbutamol empleado en crisis asmáticas y analizar las alternativas terapéuticas en esta enfermedad. Los síntomas de los efectos secundarios pueden confundirse con los causados por la propia enfermedad, por lo que puede usarse el fármaco de modo excesivo y es importante conocer el perfil posológico y caracterizar los posibles efectos secundarios en los pacientes para usar de manera racional y segura este medicamento.


Acute respiratory conditions are the first cause of consultation and hospital admission in the Winter months, being asthma the most important. Salbutamol is a bronchodilator with proven efficacy in exacerbations used first-line in treatment. The objective of this paper is to analyze two clinical cases of asthmatic children who presented adverse effects to salbutamol and required admission to the Intensive Care Unit. It is proposed to review the adverse effects of salbutamol used in asthmatic crises and to analyze therapeutic alternatives in this disease. Symptoms of side effects can be confused with those caused by the disease itself, determining the excessive use of this drug, thus, it is important to know the dosage profile and characterize the possible side effects to make rational and safe use of this drug.


As doenças respiratórias agudas são a primeira causa de consultas e internações nos meses de inverno e a asma ocupa é a mais importante. O salbutamol é um broncodilatador com eficácia comprovada nas exacerbações e é usado como tratamento de primeira linha. O objetivo desta comunicação é analisar dois casos clínicos de crianças asmáticas que apresentaram efeitos adversos ao salbutamol e necessitaram de internação em Unidade de Terapia Intensiva. Propõe-se revisar os efeitos adversos do salbutamol utilizado na crise asmática e analisar as alternativas terapêuticas nessa doença. Os sintomas de efeitos colaterais podem ser confundidos com os causados pela própria doença, determinando o uso excessivo desse medicamento, sendo importante conhecer o perfil posológico e caracterizar os possíveis efeitos colaterais nos pacientes para fazer um uso racional e seguro desse medicamento.


Asunto(s)
Humanos , Masculino , Femenino , Preescolar , Niño , Acidosis Láctica , Broncodilatadores/efectos adversos , Albuterol/efectos adversos , Hiperglucemia/inducido químicamente , Hipopotasemia/inducido químicamente , Agitación Psicomotora/etiología , Recurrencia , Asma/tratamiento farmacológico , Taquicardia/inducido químicamente , Temblor/inducido químicamente , Alucinaciones/inducido químicamente
7.
Clin Chim Acta ; 510: 232-234, 2020 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-32682800

RESUMEN

BACKGROUND: Vancomycin is used on a large scale in medical practice, mostly for the treatment of serious gram-positive bacterial infection. Many adverse effects have been linked to vancomycin use with nephrotoxicity being one of its most prevalent side effects. CASE REPORT: We present the case of an 81 years-old woman who had sustained vancomycin-induced hypokalemia while treating an infected surgical wound. She was under chronic use of losartan for high blood pressure but she was not diabetic. Potassium in serum reached critically low levels during the use of this antibiotic - despite intravenous reposition - and returned to normal right after the drug was stopped, in two different occasions. Elevated urinary potassium levels indicated renal potassium wasting, though serum creatinine levels remained within the normal range throughout hospitalization. CONCLUSIONS: Vancomycin must be considered as a possible cause for hypokalemia of unknown etiology and physicians should be aware of this potential severe adverse effect.


Asunto(s)
Hipopotasemia , Insuficiencia Renal , Anciano de 80 o más Años , Antibacterianos/efectos adversos , Femenino , Humanos , Hipopotasemia/inducido químicamente , Potasio , Vancomicina/efectos adversos
8.
J. bras. nefrol ; 42(2): 250-253, Apr.-June 2020.
Artículo en Inglés, Portugués | LILACS | ID: biblio-1134808

RESUMEN

ABSTRACT This study reports a case of a 13-year-old male with a 3-year history of severe and intermittent hypokalemia episodes of unknown origin, requiring admission to the intensive care unit (ICU) for long QT syndrome (LQTS), finally diagnosed of redistributive hypokalemia secondary to the abuse of β-adrenergic agonists in the context of a probable factitious disorder.


RESUMO O presente estudo relata o caso de um jovem de 13 anos de idade com histórico, há três anos, de episódios de hipocalemia grave intermitente de origem desconhecida, internado em unidade de terapia intensiva (UTI) por síndrome do QT longo (SQTL). O paciente foi diagnosticado com hipocalemia por redistribuição secundária ao abuso de agonistas β-adrenérgicos, em contexto de provável transtorno factício.


Asunto(s)
Humanos , Masculino , Adolescente , Síndrome de QT Prolongado/inducido químicamente , Agonistas Adrenérgicos beta/efectos adversos , Trastornos Fingidos/diagnóstico , Hipopotasemia/inducido químicamente , Potasio/sangre , Potasio/uso terapéutico , Recurrencia , Síndrome de QT Prolongado/psicología , Agonistas Adrenérgicos beta/sangre , Albuterol/sangre , Sobredosis de Droga/complicaciones , Hipopotasemia/psicología , Hipopotasemia/sangre
9.
J Bras Nefrol ; 42(2): 250-253, 2019 May 30.
Artículo en Inglés, Portugués | MEDLINE | ID: mdl-31173041

RESUMEN

This study reports a case of a 13-year-old male with a 3-year history of severe and intermittent hypokalemia episodes of unknown origin, requiring admission to the intensive care unit (ICU) for long QT syndrome (LQTS), finally diagnosed of redistributive hypokalemia secondary to the abuse of ß-adrenergic agonists in the context of a probable factitious disorder.


Asunto(s)
Agonistas Adrenérgicos beta/efectos adversos , Trastornos Fingidos/diagnóstico , Hipopotasemia/inducido químicamente , Síndrome de QT Prolongado/inducido químicamente , Adolescente , Agonistas Adrenérgicos beta/sangre , Albuterol/sangre , Sobredosis de Droga/complicaciones , Humanos , Hipopotasemia/sangre , Hipopotasemia/psicología , Síndrome de QT Prolongado/psicología , Masculino , Potasio/sangre , Potasio/uso terapéutico , Recurrencia
10.
Eur Rev Med Pharmacol Sci ; 22(20): 7034-7038, 2018 10.
Artículo en Inglés | MEDLINE | ID: mdl-30402871

RESUMEN

OBJECTIVE: Paraquat poisoning has almost disappeared from metropolitan France following its ban from the European market ten years ago. However, due to neighboring countries still authorizing paraquat use, French Guyana seems in a different situation. Here we aimed to report a series of paraquat-poisoned patients admitted to the emergency department of the Western French Guyana Hospital in Saint-Laurent du Maroni, to raise awareness of national health authorities on this persistent major issue. PATIENTS AND METHODS: We conducted a retrospective observational study describing the clinical features, the prognostic factors and the final outcome of paraquat-poisoned patients admitted to the emergency department between January 2008 and August 2014. RESULTS: Twenty-six paraquat-poisoned patients were included in the study. The median estimated paraquat dose intentionally ingested was 105 mg/kg (interquartile range, IQR: 359). Eighteen patients were treated with the cyclophosphamide/dexamethasone combination and seventeen with N-acetylcysteine in addition to the usual supportive care. Six patients survived and twenty died within a median 36h delay after admission (IQR: 130). Death was associated with cardiovascular (65%) and respiratory (35%) failure. Based on a bivariate analysis, predictive factors of death included (p≤0.05): advanced age, higher ingested paraquat dose, altered renal function, hypokalemia, acidosis, and dark blue dithionite test, observed on hospital admission. CONCLUSIONS: Paraquat poisoning still persists in French Guyana despite its withdrawal from the market. It is possible to determine the probability of death on patient admission based on routine clinical and biological parameters. There is an urgent need to request neighboring countries to ban paraquat with the aim of eradicating this dramatically life-threatening poisoning.


Asunto(s)
Paraquat/envenenamiento , Intoxicación/terapia , Salud Pública , Adolescente , Adulto , Niño , Ciclofosfamida/administración & dosificación , Servicio de Urgencia en Hospital , Femenino , Guyana Francesa/epidemiología , Humanos , Hipopotasemia/inducido químicamente , Masculino , Intoxicación/epidemiología , Estudios Retrospectivos , Adulto Joven
11.
BMC Nephrol ; 19(1): 324, 2018 11 14.
Artículo en Inglés | MEDLINE | ID: mdl-30428841

RESUMEN

BACKGROUND: Acyclovir is one of the most common prescribed antiviral drugs. Acyclovir nephrotoxicity occurs in approximately 12-48% of cases. It can present in clinical practice as acute kidney injury (AKI), crystal-induced nephropathy, acute tubulointerstitial nephritis, and rarely, as tubular dysfunction. Electrolytes abnormalities like hypokalemia, were previously described only when given intravenously. CASE PRESENTATION: A 54 year-old female presented with weakness and lower extremities paresis, nausea and vomiting after receiving oral acyclovir. Physical examination disclosed a decrease in the patellar osteotendinous reflexes (++ / ++++). Laboratory data showed a serum creatinine level of 2.1 mg/dL; serum potassium 2.1 mmol/L. Kidney biopsy was obtained; histological findings were consistent with acute tubular necrosis and acute tubulointerstitial nephritis. The patient was advised to stop the medications and to start with oral and intravenous potassium supplement, symptoms improved and continued until serum potassium levels were > 3.5 meq/L. CONCLUSIONS: The case reported in this vignette is unique since it is the first one to describe hypokalemia associated to acute tubular necrosis induced by oral acyclovir.


Asunto(s)
Aciclovir/efectos adversos , Antivirales/efectos adversos , Hipopotasemia/inducido químicamente , Hipopotasemia/patología , Necrosis Tubular Aguda/inducido químicamente , Necrosis Tubular Aguda/patología , Aciclovir/administración & dosificación , Administración Oral , Antivirales/administración & dosificación , Femenino , Humanos , Hipopotasemia/sangre , Necrosis Tubular Aguda/sangre , Persona de Mediana Edad
12.
J Med Case Rep ; 12(1): 202, 2018 Jul 11.
Artículo en Inglés | MEDLINE | ID: mdl-29991348

RESUMEN

BACKGROUND: Severe hyponatremia is rare when carbamazepine is used as monotherapy. It is common to encounter this imbalance in the hospital setting, but rare in the ambulatory one. Here, we present a case of hyponatremia secondary to carbamazepine use in an otherwise asymptomatic patient. CASE PRESENTATION: A 44-year-old Guatemalan woman presented to our outpatient clinic with a chief complaint of left knee pain. One month prior, our patient had previously consulted with an outside physician, who prescribed her with 300 mg of carbamazepine, 5 mg of prednisone every 24 hours, and ibuprofen every 8 hours as needed. The symptoms did not resolve and our patient had increased the dose to 600 mg of carbamazepine and 20 mg of prednisone 7 days prior. Our patient complained of left knee pain, fatigue, and bilateral lower limb cramps. No pertinent medical history was recorded and her vital signs were within normal limits. A physical examination was non-contributory, only multiple port-wine stains in the upper and lower extremities associated with mild hypertrophy of the calves, more prominent on the right side. Laboratory studies revealed: a serum sodium level of 119 mmol/L, potassium level of 2.9 mmol/L, thyroid-secreting hormone of 1.76 mIU/m, thyroxine of 14.5 ng/dL, and serum osmolality at 247 mmol/kg. No neurologic or physical disabilities were recorded. In the emergency department, her electrolyte imbalance was corrected and other diagnostic studies revealed: a urinary sodium level of 164 mmol/L and osmolality at 328 mmol/kg. Our patient was diagnosed with syndrome of inappropriate antidiuretic hormone secretion secondary to carbamazepine use, hypokalemia secondary to corticosteroid therapy, and Klippel-Trénaunay-Weber syndrome. Carbamazepine was discontinued, fluid restriction ordered, and hypokalemia was corrected. One week after discharge, our patient no longer felt fatigued, the cramps were not present, and her left knee pain had mildly improved with acetaminophen use and local nonsteroidal anti-inflammatory cream. Electrolyte studies revealed a sodium level of 138 mmol/L, potassium level of 4.6 mmol/L, and serum osmolality at 276 mmol/L. CONCLUSIONS: Hyponatremia can be misdiagnosed if not recognized promptly; suspicion should be high when risk factors are present and the patient has been prescribed antiepileptic drugs. Presence of mild symptoms such as fatigue or dizziness should lead to suspicion and subsequent laboratory testing. Patients can suffer from neurologic complications if the imbalance is not corrected.


Asunto(s)
Analgésicos no Narcóticos/efectos adversos , Carbamazepina/efectos adversos , Hiponatremia/inducido químicamente , Síndrome de Secreción Inadecuada de ADH/inducido químicamente , Dolor/tratamiento farmacológico , Adulto , Atención Ambulatoria , Animales , Bovinos , Femenino , Humanos , Hipopotasemia/inducido químicamente , Hipopotasemia/terapia , Hiponatremia/terapia , Ibuprofeno/uso terapéutico , Síndrome de Secreción Inadecuada de ADH/terapia , Síndrome de Klippel-Trenaunay-Weber/diagnóstico , Rodilla , Prednisolona/efectos adversos , Prednisolona/uso terapéutico
13.
Rev Fac Cien Med Univ Nac Cordoba ; 75(4): 310-313, 2018 11 13.
Artículo en Inglés | MEDLINE | ID: mdl-30734712

RESUMEN

Rhabdomyolysis results from acute necrosis of skeletal muscle fibres and consequent leakage of muscle constituents into the circulation. Its association with anything different than trauma in the Emergency Room is not that frequent. We present the case of a 47-year-old male, hypertensive, that developed weakness and incapability to walk without help, finding on the blood biochemistry that he had developed a rhabdomyolysis due to hipokalemia after abusing of diuretics.


La rabdomiólisis es el resultado de la necrosis de las fibras musculoesqueléticas y la consiguiente fuga de constituyentes musculares a la circulación. Su asociación con algo diferente a un trauma en la sala de emergencias no es tan frecuente. Presentamos el caso de un varón de 47 años, hipertenso, con historia de abuso de diuréticos, desarrollando debilidad e incapacidad para caminar por sus propios medios, encontrando en la bioquímica sanguínea que había padecía rabdomiólisis por hipocalemia.


Asunto(s)
Diuréticos/envenenamiento , Hipopotasemia/inducido químicamente , Hipopotasemia/complicaciones , Rabdomiólisis/etiología , Humanos , Hipopotasemia/diagnóstico , Masculino , Persona de Mediana Edad , Potasio/uso terapéutico , Sierra Leona
14.
PM R ; 10(5): 544-547, 2018 05.
Artículo en Inglés | MEDLINE | ID: mdl-29074369

RESUMEN

A 30-year-old man with no significant medical history presented with hypokalemic quadriplegia 4 hours after he received a lumbar transforaminal epidural steroid injection (ESI) containing dexamethasone and lidocaine. A comprehensive workup ruled out acquired and hereditary causes of hypokalemic paralysis. Symptoms gradually resolved within hours after potassium restoration with no residual neurologic deficits. Paralysis after transforaminal ESI is uncommon but has been associated with particulate steroids that can coalesce into aggregates and occlude vessels. To our knowledge, there have been no case reports of paralysis after ESI with dexamethasone, a nonparticulate steroid. This transient paralysis is possibly caused by the effects of glucocorticoids on Na-K channels and insulin resistance resulting in hyperglycemia and subsequent hypokalemia. We reviewed the differential diagnosis of transient paralysis after epidural steroid injection in this report. LEVEL OF EVIDENCE: IV.


Asunto(s)
Dexametasona/efectos adversos , Hipopotasemia/inducido químicamente , Dolor de la Región Lumbar/tratamiento farmacológico , Cuadriplejía/inducido químicamente , Adulto , Dexametasona/administración & dosificación , Fluoroscopía , Estudios de Seguimiento , Glucocorticoides/administración & dosificación , Glucocorticoides/efectos adversos , Humanos , Hipopotasemia/complicaciones , Inyecciones Epidurales/efectos adversos , Dolor de la Región Lumbar/diagnóstico , Vértebras Lumbares , Masculino , Cuadriplejía/etiología
15.
Int J STD AIDS ; 28(12): 1259-1262, 2017 10.
Artículo en Inglés | MEDLINE | ID: mdl-28403692

RESUMEN

A 60-year-old HIV-1 infected woman on antiretroviral therapy (emtricitabine/tenofovir, and ritonavir-boosted atazanavir) developed Hodgkin's lymphoma. The patient initiated ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) chemotherapy and presented with neutropenia and severe hypokalemia. Hypokalemia was considered as part of a proximal tubular renal dysfunction, and other causes of hypokalemia were excluded. Due to suspicion of drug--drug interactions between antiretrovirals and vinblastine, ritonavir-boosted atazanavir was switched to dolutegravir and the patient continued emtricitabine/tenofovir. In the subsequent ABVD cycles, no neutropenia or hypokalemia were observed. Vinblastine is metabolized by the hepatic P450 cytochrome isoenzyme CYP3A4, therefore, concomitant administration with protease inhibitors may increase plasma levels of vinblastine. Vinblastine is also a substrate and inhibitor of multidrug resistance-associated protein 2 (MRP2) transporter in the proximal renal tubule. Inhibition of this renal transporter could increase tenofovir renal toxicity. Our hypothesis is that the hypokalemia could be a result of a tenofovir-mediated tubular damage triggered by the increased vinblastine serum levels secondary to a CYP3A4 inhibition by ritonavir. To the best of our knowledge, this is the first report of severe hypokalemia and proximal tubular renal dysfunction as a result of a possible drug-drug interaction between vinblastine, tenofovir and ritonavir-boosted atazanavir.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Infecciones por VIH/tratamiento farmacológico , Inhibidores de la Proteasa del VIH/administración & dosificación , Enfermedad de Hodgkin/tratamiento farmacológico , Hipopotasemia/inducido químicamente , Ritonavir/administración & dosificación , Vinblastina/administración & dosificación , Adenina/administración & dosificación , Adenina/análogos & derivados , Protocolos de Quimioterapia Combinada Antineoplásica/farmacocinética , Bleomicina/administración & dosificación , Dacarbazina/administración & dosificación , Doxorrubicina/administración & dosificación , Interacciones Farmacológicas , Emtricitabina/administración & dosificación , Femenino , Infecciones por VIH/inmunología , Inhibidores de la Proteasa del VIH/farmacocinética , Enfermedad de Hodgkin/inmunología , Enfermedad de Hodgkin/virología , Humanos , Persona de Mediana Edad , Ritonavir/farmacocinética , Tenofovir/administración & dosificación , Resultado del Tratamiento , Vinblastina/farmacocinética
16.
Vertex ; 28(134): 271-279, 2017 Jul.
Artículo en Español | MEDLINE | ID: mdl-29522591

RESUMEN

The purpose of this report is to emphasize the necessity to periodically explore internal environment variables, as certain metabolic alterations often go unnoticed during antipsychotic treatment. Early detection of such alterations may prevent catastrophic syndromes. We will also stress the clinical relevance of cognitive perseverations in schizophrenic patients, as these often condition habits of consumption which can alter the internal environment. In this clinical case of a schizophrenic patient, a chain of events led to a catastrophic syndrome: a trivial home accident (fall from own height) developed into a condition characterized by oligoanuria, hypokalemia, creatine phosphokinase (CPK) elevation (125,000 IU / L) and acute renal failure with dialysis requirement. This episode was non lethal due to the early implementation of support measures. We performed a revision of the available literature in order to discern the cause of the elevation of CPK. Here we aim to highlight the importance of 1) careful clinical and laboratory monitoring of psychopharmacological treatment, 2) interactions resulting from consumption habits capable of generating unforeseen consequences, 3) the role of the psychiatrist in the context of multidisciplinary work.


Asunto(s)
Antipsicóticos/efectos adversos , Hipopotasemia/inducido químicamente , Rabdomiólisis/inducido químicamente , Esquizofrenia/tratamiento farmacológico , Antipsicóticos/uso terapéutico , Humanos , Hipopotasemia/complicaciones , Masculino , Persona de Mediana Edad , Rabdomiólisis/complicaciones
17.
J Clin Pharmacol ; 56(12): 1507-1515, 2016 12.
Artículo en Inglés | MEDLINE | ID: mdl-27198583

RESUMEN

The aim of the present study was to determine the frequency of adverse drug reactions (ADRs) associated with the use of systemic antifungal drugs in patients hospitalized at a high-complexity hospital. In addition, factors associated with ADRs were investigated. This cross-sectional retrospective study involved the investigation of 183 medical records of patients receiving systemic antifungal therapy. Antifungal drugs were classified using the fourth level of the Anatomical Therapeutic Chemical System. ADR causality was classified using the Naranjo algorithm. Drug interactions were assessed using DRUG-REAX software. Data were analyzed with descriptive statistics and univariate and multivariate logistic regression. A total of 53 patients (29.0%) had at least 1 ADR involving antifungals. Ninety-six ADRs were detected. The main ADRs observed were an infusion reaction in 24 patients (25.0%), hypokalemia in 22 (22.9%), nephrotoxicity in 18 (18.7%), and hepatotoxicity in 15 (15.6%). Amphotericin B and voriconazole were associated with ADRs of major clinical impact. Eleven of the ADRs (11.4%) were related to drug interactions. The following 3 factors were contributors to the multivariate model for the occurrence of ADRs caused by antifungal drug use: neoplasm diagnosis (odds ratio [OR], 3.9; 1.9-7.9), length of hospital stay (OR, 2.2; 1.1-4.5), and the use of ≥13 drugs (OR, 3.4; 1.6-7.2). Our study revealed positive associations between the occurrence of ADRs and diagnosis of a neoplasm, the length of stay, and the use of multiple drugs concomitant with antifungals. These risk factors should be considered in antifungal stewardship, among other actions, to promote the rational use of antifungal agents.


Asunto(s)
Antifúngicos/efectos adversos , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/diagnóstico , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/epidemiología , Hospitalización/tendencias , Hospitales Públicos/tendencias , Lesión Renal Aguda/inducido químicamente , Lesión Renal Aguda/diagnóstico , Lesión Renal Aguda/epidemiología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Niño , Preescolar , Estudios Transversales , Femenino , Humanos , Hipopotasemia/inducido químicamente , Hipopotasemia/diagnóstico , Hipopotasemia/epidemiología , Lactante , Recién Nacido , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Adulto Joven
19.
BMC Emerg Med ; 15: 19, 2015 Aug 18.
Artículo en Inglés | MEDLINE | ID: mdl-26282250

RESUMEN

BACKGROUND: Toluene is one of the most widely abused inhaled drugs due to its acute neurologic effects including euphoria and subsequent depression. However, dangerous metabolic abnormalities are associated to acute toluene intoxication. It has been previously reported that rhabdomyolysis and acute hepatorenal injury could be hallmarks of the condition, and could constitute risk factors for poor outcomes. The objective was to describe the clinical presentation, to characterize the renal and liver abnormalities, the management and prognosis associated to acute toluene intoxication. METHODS: We prospectively assessed 20 patients that were admitted to a single center's emergency department from September 2012 to June 2014 with clinical and metabolic alterations due to acute toluene intoxication. RESULTS: The main clinical presentation consisted of weakness associated to severe hypokalemia and acidosis. Renal glomerular injury (proteinuria) is ubiquitous. Biliary tract injury (alkaline phosphatase and gamma-glutamyl transpeptidase elevations) disproportional to hepatocellular injury is common. Rhabdomyolysis occurred in 80% of patients, probably due to hypokalemia and hypophosphatemia. There were three deaths, all female, and all associated with altered mental status, severe acidosis, hypokalemia and acute oliguric renal failure. The cause of death was in all cases due to cardiac rhythm abnormalities. CONCLUSION: The hallmarks of acute toluene intoxication are hypokalemic paralysis and metabolic acidosis. Liver injury and rhabdomyolysis are common. On admission, altered mental status, renal failure, severe acidemia and female gender (not significant in our study, but present in all three deaths) could be associated with a poor outcome, and patients with these characteristics should be considered to be treated in an intensive care unit.


Asunto(s)
Drogas Ilícitas/envenenamiento , Trastornos Relacionados con Sustancias/diagnóstico , Tolueno/envenenamiento , Acidosis/inducido químicamente , Enfermedad Aguda , Adolescente , Adulto , Enfermedades de las Vías Biliares/inducido químicamente , Enfermedad Hepática Inducida por Sustancias y Drogas/etiología , Cuidados Críticos , Femenino , Humanos , Hipopotasemia/inducido químicamente , Modelos Logísticos , Masculino , Parálisis/inducido químicamente , Pronóstico , Estudios Prospectivos , Proteinuria/inducido químicamente , Rabdomiólisis/inducido químicamente , Factores de Riesgo , Trastornos Relacionados con Sustancias/complicaciones , Trastornos Relacionados con Sustancias/mortalidad , Trastornos Relacionados con Sustancias/terapia , Adulto Joven
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA